A new trading day began on Friday, with Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) stock price up 5.02% from the previous day of trading, before settling in for the closing price of $51.23. CRNX’s price has ranged from $25.35 to $55.78 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 64.83% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -0.22%. With a float of $75.22 million, this company’s outstanding shares have now reached $80.04 million.
In an organization with 290 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -27.22%, operating margin of -20143.39%, and the pretax margin is -18667.15%.
Crinetics Pharmaceuticals Inc (CRNX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 6.01%, while institutional ownership is 100.51%. The most recent insider transaction that took place on Sep 10 ’24, was worth 53,302. In this transaction Chief Scientific Officer of this company sold 1,035 shares at a rate of $51.50, taking the stock ownership to the 68,576 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Officer proposed sale 1,035 for $51.50, making the entire transaction worth $53,301.
Crinetics Pharmaceuticals Inc (CRNX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -0.22% per share during the next fiscal year.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Here are Crinetics Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.77, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -3.89 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.54 million. That was inferior than the volume of 0.79 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.60%. Additionally, its Average True Range was 2.08.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 86.59%, which indicates a significant increase from 68.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.74% in the past 14 days, which was lower than the 43.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.90, while its 200-day Moving Average is $44.06. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $54.57. Second resistance stands at $55.34. The third major resistance level sits at $56.83. If the price goes on to break the first support level at $52.31, it is likely to go to the next support level at $50.82. The third support level lies at $50.05 if the price breaches the second support level.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
With a market capitalization of 4.31 billion, the company has a total of 78,860K Shares Outstanding. Currently, annual sales are 4,010 K while annual income is -214,530 K. The company’s previous quarter sales were 400 K while its latest quarter income was -74,050 K.
